In Kidney, the Name Game not Just ‘A-Cute’ Switcheroo
October 31, 2012 – 1:42 pm | By Randy Osborne | No comments yet
I was on the phone last week with Rick Andrews, president and CEO of Thrasos, about acute kidney injury (AKI), and how it’s no longer called “acute renal failure,” the latter phrase having been scrapped in recent years.
Read moreThe Times They Are A-Changin’
October 15, 2012 – 1:15 pm | By Peter Winter | No comments yet
Kudos to the folks at Biotechnology Industry Organization (BIO) for selecting the industry’s “hot button” issues for panel discussions at the annual BIO Investor Forum (BIF) just concluded in San Francisco. In years past it has been my experience that…
Read moreForce Care Foundation Brings Military Opportunities to Bio-Entrepreneurs
October 10, 2012 – 3:54 pm | By Guest Contributor | 1 comment
Last autumn, I was searching for a way to get rid of the nerve-zapping pain that hit every time the barometer made a steep jump. My face full of post-plane crash titanium and regenerated bone acted like a weather station….
Read moreWhat Global Financial Crisis? Capital Markets Back Biotechs
October 3, 2012 – 11:19 am | By Peter Winter | No comments yet
It is that time of year again when we take the pulse of the industry at the close of the third quarter. Overall we find that it is performing well, more so for public biotechs than private ones. Despite the…
Read moreA Modest Proposal to the IgNobel Committee
September 26, 2012 – 3:27 pm | By Anette Breindl | No comments yet
I always love reading about the IgNobel Prizes. The stated goal of the prize is to reward research that “first makes people laugh, and then makes them think.” And this year’s crop of winners once again succeeds at those tasks.
Read more‘Final Chapter’ on XMRV? Good Luck With That One
September 24, 2012 – 11:42 am | By Anette Breindl | 1 comment
Viruses are on the border between living and dead. So are the theories about what some of them cause.
Read moreLife Isn’t as Sweet as it May Seem in Biotech’s C-Suites
September 18, 2012 – 5:12 pm | By Michael Harris | No comments yet
Biotechnology is an idiosyncratic industry in which some executives can stake their careers on the pursuit of orphan drugs that, at best, will offer only limited opportunity for corporate profits and investors returns, while addressing the usually unmet needs of…
Read moreGrappling with the Ethics
September 5, 2012 – 9:45 am | By Mari Serebrov | No comments yet
With science boldly taking us where we’ve never gone before, we’re exploring new worlds and stretching the boundaries of our universe. While these are exciting times for the adventurer in us, they can be discomfiting for our inner ethicist.
Read moreWhere’s Rube Goldberg When You Need Him?
August 8, 2012 – 10:36 am | By Mari Serebrov | 2 comments
What’s the difference between Congress and a Rube Goldberg contraption?
Read moreIs it Better to Forgive and Pharm-merge?
August 6, 2012 – 4:26 pm | By Michael Harris | No comments yet
Aug. 5 was International Forgiveness Day, and the founding organization of this annual effort, Worldwide Forgiveness Alliance (WFA), says in its mission statement that a goal is to promote and publicize the research findings that show forgiveness creates better health,…
Read more
Join the Conversation